Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma

BACKGROUND: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that has been approved for the treatment of metastatic renal cell carcinoma. Although the majority of sunitinib-treated patients receive a clinical benefit, almost a third of the patients will not respond. Currently there is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Papazisis, Konstantinos T, Kontovinis, Lukas F, Papandreou, Christos N, Kouvatseas, George, Lafaras, Christos, Antonakis, Evangelos, Christopoulou, Maria, Andreadis, Charalambos, Mouratidou, Despoina, Kortsaris, Alexandros H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946311/
https://www.ncbi.nlm.nih.gov/pubmed/20840755
http://dx.doi.org/10.1186/1471-2407-10-489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946311/
https://www.ncbi.nlm.nih.gov/pubmed/20840755
http://dx.doi.org/10.1186/1471-2407-10-489

Ejemplares similares